<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>255-GRISEOFULVIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRISEOFULVIN" rxcui="5021">
<ATC code="D01AA08" />
<ATC code="D01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the griseofulvin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with griseofulvin and a week after it is stopped </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>255-GRISEOFULVIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRISEOFULVIN" rxcui="5021">
<ATC code="D01AA08" />
<ATC code="D01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the contraceptive effectiveness due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Another method of contraception, in particular a barrier type, should be used during the time the two substances are administered together and a cycle after. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>255-GRISEOFULVIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="GRISEOFULVIN" rxcui="5021">
<ATC code="D01AA08" />
<ATC code="D01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use a reliable contraceptive method, additional or alternative, during the length of time these substances are administered together and a cycle following.</COMMENT>
</INTERACTION>
</INTERACTIONS>
